Risk factor
Negligible price volatility
Profitability factor
Undervalued vs peers
About
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine...
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITDA, trading at neutral le
Target Price
The average target price of HLUN-B.CO is 46 and suggests 7% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio
Buy
Sell